Allogeneic hematopoietic cell transplant for CML blast crisis OR multi-TKI failure
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-ALLOHCT-CML-ADVANCED |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ELN-CML-2020 SRC-NCCN-MPN-2025 |
Notes
AlloHCT remains the only curative option for CML in blast crisis or after multi-TKI failure without ponatinib/asciminib access. Outcomes best with optimal disease control pre-HCT (target ≥CCyR or MMR). Post-HCT TKI maintenance (typically dasatinib or imatinib) for ≥2 years reduces relapse. STUB — pending Co-Lead sign-off. Conditioning regimen selection institution-specific — this entity is a placeholder pointing to alloHCT pathway, not a fully specified chemotherapy regimen.
Used By
Indication
IND-CML-ADVANCED-ALLOHCT- IND-CML-ADVANCED-ALLOHCT